Regeneron slides as Amgen wins Eylea biosimilar case; RBC still bullish Investing.com Regeneron slides as Amgen wins Eylea biosimilar case; RBC still bullish. Amgen (AMGN) 5 hours
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea Investor's Business Daily 9 hours
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data Seeking Alpha 2 weeks
How This Amgen Rival Is Taking On The Company’s $28 Billion Acquisition Investor's Business Daily 2 weeks
Amgen Inc. (AMGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript) Seeking Alpha 3 weeks
The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race Investor's Business Daily 4 weeks
Why Biotech Giant Amgen Stands A Chance Of Taking On Novo, Lilly In Obesity Investor's Business Daily 2 months
Novartis Dives After Handing Amgen, Bristol — And Their Rivals — A Key Victory Investor's Business Daily 2 months
Amgen Inc. (AMGN): Hedge Funds Are Bullish on This Blue Chip Dividend Stock Now Insider Monkey 3 months